A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
The purpose of this study is to evaluate the safety and effectiveness of the study drug Mirikizumab in participants with active Crohn's Disease.
Inclusion Criteria:
Exclusion Criteria:
Ústí nad Labem, Czech Republic 40113, Czechia
Praha 4 - Krc, 140 59, Czechia
Sakura-shi, Chiba 285 8471, Japan
Kitakyusyu-shi, Fukoka 802-0077, Japan
Kamakura-shi, Kanagawa 247-0056, Japan
Bunkyo-ku, Tokyo 113-8519, Japan
Shinjuku-ku, Tokyo 169-0073, Japan
Kyiv, 04107, Ukraine